Caffeine as a neuroprotective adenosine receptor antagonist.
Dall'Igna
Oscar P
OP
Department of Biochemistry, ICBS, Universidade Federal Do Rio Grande do Sul, Porto Alegre, Brazil. oscard@terra.com.br
Souza
Diogo O
DO
Lara
Diogo R
DR
D058916:Adenosine A1 Receptor Antagonists; D058917:Adenosine A2 Receptor Antagonists; D000544:Alzheimer Disease / Q000188:drug therapy; D000818:Animals; D002110:Caffeine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy
D058916:Adenosine A1 Receptor Antagonists; D058917:Adenosine A2 Receptor Antagonists; D018696:Neuroprotective Agents; D002110:Caffeine